Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Discontinuation Symptoms of Desvenlafaxine in MDD
NCT01056289Phase 4Completed
- Sponsor
- Pfizer
- Start
- Mar 2010
- Primary completion
- Feb 2011
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial of desvenlafaxine in major depressive disorder (MDD) (3 arms), sponsored by Pfizer. Primary endpoint: Total Discontinuation - Emergent Signs and Symptoms Score at 2 weeks. Started Mar 2010; status: completed.
02
Drugs
desvenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01056289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01056289.